Lexeo Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 12, 2025
LXEO$3.06-2.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Stockholders’ Equity (unaudited)
Condensed Statements of Stockholders’ Equity
(Unaudited, in thousands, except share amounts)
| Accumulated | |||||||
|---|---|---|---|---|---|---|---|
| Additional · Other · Total | |||||||
| Common Stock · Treasury · Paid-in · Comprehensive · Accumulated · Stockholders' | |||||||
| Shares | Amount | Stock | Capital | Income (Loss) | Deficit | Equity | |
| Balances at December 31, 2024 | 33,071,261 | $3 | $(17) | $397,132 | $(103) | $(280,173) | $116,842 |
| Issuance of common stock upon vesting and settlement of restricted stock units | 52,446 | - | - | - | - | - | - |
| Issuance of common stock under 2023 ESPP | 65,342 | - | - | 170 | - | - | 170 |
| Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase | 2,816 | - | - | 13 | - | - | 13 |
| Unrealized comprehensive gain on investments | - | - | - | - | 49 | - | 49 |
| Stock-based compensation expense | - | - | - | 3,697 | - | - | 3,697 |
| Net loss | - | - | - | - | - | (32,656) | (32,656) |
| Balances at March 31, 2025 | 33,191,865 | $3 | $(17) | $401,012 | $(54) | $(312,829) | $88,115 |
| Accumulated | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Additional · Other · Total | |||||||||
| Common Stock · Treasury · Paid-in · Comprehensive · Accumulated · Stockholders' | |||||||||
| Shares · Amount · Stock · Capital · Income (Loss) · Deficit · Equity | |||||||||
| Balances at December 31, 2023 | 26,646,378 | $3 | $ | - | $295,372 | $ | - | $(181,840) | $113,535 |
| Exercise of stock options | 942 | - | - | 10 | - | - | 10 | ||
| Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase | 1,916 | - | - | 3 | - | - | 3 | ||
| Issuance of common stock upon private placement offering, net of commissions and offering costs of $6,246 | 6,278,905 | - | - | 88,753 | - | - | 88,753 | ||
| Stock-based compensation expense | - | - | - | 2,331 | - | - | 2,331 | ||
| Net loss | - | - | - | - | - | (21,682) | (21,682) | ||
| Balances at March 31, 2024 | 32,928,141 | $3 | $ | - | $386,469 | $ | - | $(203,522) | $182,950 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.